Crohn's disease therapeutic - Eli Lilly
Latest Information Update: 30 May 2016
At a glance
- Originator Eli Lilly
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Crohn's disease
Most Recent Events
- 23 Jan 2014 Phase-I clinical trials in Crohn's disease in USA (unspecified route)